Unsuspected placenta accreta spectrum at vaginal delivery: assessment of incidence, characteristics, and maternal morbidity

被引:3
作者
Rau, Alesandra R. [1 ,2 ]
Youssefzadeh, Ariane C. [1 ]
Matsuzaki, Shinya [1 ]
Mandelbaum, Rachel S. [1 ,3 ]
Ouzounian, Joseph G. [4 ]
Matsuo, Koji [1 ,5 ]
机构
[1] Univ Southern Calif, Dept Obstet & Gynecol, Div Gynecol Oncol, Los Angeles, CA 90007 USA
[2] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[3] Univ Southern Calif, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Los Angeles, CA USA
[4] Univ Southern Calif, Dept Obstet & Gynecol, Div Maternal Fetal Med, Los Angeles, CA USA
[5] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA
关键词
characteristics; maternal morbidity; placenta accreta spec-trum; unsuspected; vaginal delivery; FIGO CONSENSUS GUIDELINES; RISK-FACTORS; DIAGNOSIS; MANAGEMENT; FIBROIDS; OUTCOMES;
D O I
10.1016/j.ajogmf.2022.100805
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
BACKGROUND: Placenta accreta spectrum refers to morbidly adher-ent trophoblastic tissue invading into the gravid uterus and is associated with significant maternal morbidity. Most cases of placenta accreta spec-trum are suspected antenatally, and most patients undergo planned, late-preterm cesarean hysterectomy to reduce the risk of morbidity. Rarely, however, placenta accreta spectrum is incidentally diagnosed at vaginal delivery, but there is a scarcity of data regarding these events.OBJECTIVE: This study aimed to examine the incidence, characteris-tics, and outcomes of pregnant individuals with incidentally diagnosed pla-centa accreta spectrum at term vaginal delivery.STUDY DESIGN: This was a retrospective cohort study investigating the Healthcare Cost and Utilization Project's National Inpatient Sample. The study population was 8,694,669 term vaginal deliveries from January 2016 to December 2019. Exclusion criteria included previous uterine scar, placenta previa, and preterm delivery. Exposure was assigned by the diagnosis of placenta accreta spectrum. The main outcomes were: (1) incidence rate, (2) clinical and pregnancy characteristics, and (3) maternal morbidity related to unsuspected placenta accreta spectrum at vaginal delivery. Multivariable binary logistic regression analysis and inverse prob-ability of treatment weighting were fitted for statistical analysis.RESULTS: Unsuspected placenta accreta spectrum was reported in 1 in 3797 vaginal deliveries. In a multivariable analysis, the following were associated with increased likelihood of unsuspected placenta accreta spectrum (all, P<.05): (1) patient factor with older age, (2) uterine factors such as uterine anomaly and uterine myoma, (3) preg-nancy factors including early-term delivery and previous recurrent pregnancy losses, and (4) fetal factors of in utero growth restriction and demise. Of those, uterine anomaly had the greatest association with unsuspected placenta accreta spectrum (adjusted odds ratio, 6.23; 95% confidence interval, 4.20-9.26). In a propensity score -weighted model, patients in the unsuspected placenta accreta spec-trum group were more likely to have hemorrhage (65.2% vs 4.1%), blood product transfusion (21.3% vs 0.6%), hysterectomy (14.9% vs <0.1%), coagulopathy (2.9% vs 0.1%), and shock (2.9% vs <0.1%) compared with those without placenta accreta spectrum. Patients in the unsuspected placenta accreta spectrum group were also more likely to receive manual removal of the placenta compared with those in the non-placenta accreta spectrum group (25.1% vs 0.6%).CONCLUSION: This study suggests that although unsuspected pla-centa accreta spectrum among patients undergoing term vaginal delivery is rare, it is associated with significant morbidity. The observed association between uterine anomalies and placenta accreta spectrum warrants fur-ther investigation.
引用
收藏
页数:9
相关论文
共 35 条
[1]   Increased placental trophoblast inclusions in placenta accreta [J].
Adler, E. ;
Madankumar, R. ;
Rosner, M. ;
Reznik, S. E. .
PLACENTA, 2014, 35 (12) :1075-1078
[2]   Placenta Accreta An Association With Fibroids and Asherman Syndrome [J].
Al-Serehi, Amal ;
Mhoyan, Anna ;
Brown, Michelle ;
Benirschke, Kurt ;
Hull, Andrew ;
Pretorius, Dolores H. .
JOURNAL OF ULTRASOUND IN MEDICINE, 2008, 27 (11) :1623-1628
[3]   OBSTETRIC CARE CONSENSUS NO. 7 SUMMARY: Placenta Accreta Spectrum. [J].
不详 .
OBSTETRICS AND GYNECOLOGY, 2018, 132 (06) :1519-1521
[4]  
[Anonymous], 2013, Obstet Gynecol, V122, P1139, DOI 10.1097/01.AOG.0000437385.88715.4a
[5]   Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies [J].
Austin, Peter C. ;
Stuart, Elizabeth A. .
STATISTICS IN MEDICINE, 2015, 34 (28) :3661-3679
[6]   Uterine body placenta accreta spectrum: A detailed literature review [J].
Badr, Dominique A. ;
Al Hassan, Jihad ;
Wehbe, Georges Salem ;
Ramadan, Mohamad K. .
PLACENTA, 2020, 95 :44-52
[7]   Morbidly Adherent Placenta Treatments and Outcomes [J].
Bailit, Jennifer L. ;
Grobman, William A. ;
Rice, Madeline Murguia ;
Reddy, Uma M. ;
Wapner, Ronald J. ;
Varner, Michael W. ;
Leveno, Kenneth J. ;
Iams, Jay D. ;
Tita, Alan T. N. ;
Saade, George ;
Rouse, Dwight J. ;
Blackwell, Sean C. .
OBSTETRICS AND GYNECOLOGY, 2015, 125 (03) :683-689
[8]   Antecedents of Abnormally Invasive Placenta in Primiparous Women Risk Associated With Gynecologic Procedures [J].
Baldwin, Heather J. ;
Patterson, Jillian A. ;
Nippita, Tanya A. ;
Torvaldsen, Siranda ;
Ibiebele, Ibinabo ;
Simpson, Judy M. ;
Ford, Jane B. .
OBSTETRICS AND GYNECOLOGY, 2018, 131 (02) :227-233
[9]   Placenta Accreta Spectrum [J].
Cahill, Alison G. ;
Beigi, Richard ;
Heine, R. Phillips ;
Silver, Robert M. ;
Wax, Joseph R. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 219 (06) :B2-B16
[10]   Placenta Accreta Spectrum Without Placenta Previa [J].
Carusi, Daniela A. ;
Fox, Karin A. ;
Lyell, Deirdre J. ;
Perlman, Nicola C. ;
Aalipour, Soroush ;
Einerson, Brett D. ;
Belfort, Michael A. ;
Silver, Robert M. ;
Shamshirsaz, Alireza A. .
OBSTETRICS AND GYNECOLOGY, 2020, 136 (03) :458-465